inDrive Calls for Justice in Tech Leadership; Launches Global Campaign to Recruit Directors for Child Protection, Education, and Good Governance
27.10.2025 14:00:00 CET | Business Wire | Press Release
inDrive, the world’s second most downloaded ride-hailing app, has set a bold goal: to positively impact 1 billion people by 2030. To achieve it, the company is strengthening its impact arm and launching “Positions of Purpose,” a global campaign to recruit senior leaders in child protection, education, and governance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027308855/en/
inDrive, a global mobility and urban services platform, extends mission-driven approach from business model to hiring practices.
inDrive first challenged the ride-hailing model by allowing riders and drivers to negotiate fares directly, building a business on fairness instead of opaque pricing. Now, the company is challenging what impact hiring should look like — putting social justice roles at the same level of priority and visibility as growth, product, and operations.
The campaign introduces three unprecedented roles:
- Global Director, Family-Based Care in Child Protection
- Global Director, Education Policy and Systems Strengthening
- Global Director, Impact Governance and Public Policy
Unlike traditional tech companies that typically hire for growth, development, and operations, inDrive is integrating its founding principles of fairness and social impact directly into its organizational structure. The company’s approach reflects a belief that good business means being part of the community, understanding what is missing, and filling that gap. inDrive’s impact team, now consisting of over 70 dedicated professionals, runs 8 in-house programs, spanning education, sports, women’s entrepreneurship, air quality and driver empowerment.
With this move, inDrive is further extending its mission of “challenging injustice” from its business model into its leadership structure. The company operates in nearly 1000 cities across 48 countries, and says its next phase is about scaling impact through its social programs as much as through fair deals on its platform.
“We operate across many emerging and underserved markets. If our mission is to challenge injustice, we have to build the leadership capacity to deliver it at scale,” said Arsen Tomsky, Founder and CEO of inDrive. “These roles will help us translate intent into impact - strengthening families, improving education systems, and advancing good governance.”
Beyond these new roles, the company is also hiring for a broader range of positions that bridge business and social impact. Candidates who want to ensure their next role — whether in marketing, partnerships, governmental affairs, or other areas — contributes to meaningful change can now easily find these listings on inDrive’s career website, marked with the “Positions of Purpose” label.
The campaign reframes hiring itself as a platform for advocacy, using LinkedIn and Meta, directing applicants to a dedicated landing page aligned with the company’s careers site.
The company is offering competitive compensation packages and welcomes candidates from both business and nonprofit backgrounds. All roles are remote-eligible.
For more information about the job roles, please visit: https://careers.indrive.com/positions-of-purpose/
About inDrive
inDrive is a global mobility and urban services platform. The inDrive app has been downloaded over 360 million times, and has been named the second most downloaded mobility app for the third consecutive year. In addition to ride-hailing, inDrive provides an expanding list of services, including intercity transportation, delivery, and financial services. In 2023, inDrive launched New Ventures, a venture and M&A arm.
inDrive operates in 982 cities in 48 countries. Driven by its mission of challenging injustice, the company is committed to having a positive impact on the lives of one billion people by 2030. It pursues this goal both through its core business, which supports local communities via a fair pricing model; and through the work of its impact programs.
For more information visit www.inDrive.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251027308855/en/
Contacts
indrive@snowhilladvisors.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom